https://crcwarriors.org/ 2026-07-30 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-07-30 daily 0.9 https://crcwarriors.org/medicamentos 2026-07-30 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-07-30 daily 0.8 https://crcwarriors.org/noticias 2026-07-30 daily 0.8 https://crcwarriors.org/combinaciones 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-07-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-07-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-07-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-07-01 monthly 0.7 https://crcwarriors.org/contacto 2026-07-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-07-01 monthly 0.6 https://crcwarriors.org/colabora 2026-07-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07720505/coloflow-imagenologia-de-contraste-de-motas-laser-frente-a-imagenologia-de-fluorescencia-en-el-infrarrojo-cercano-con-verde-de-indocianina 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07720505/coloflow-laser-speckle-contrast-imaging-versus-near-infrared-fluorescence-imaging-with-indocyanine-green 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07720245/eficacia-de-una-aplicacion-movil-de-autoevaluacion-de-la-salud-en-adultos-jovenes-y-de-mediana-edad-en-hong-kong 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07720245/effectiveness-of-a-self-health-assessment-mobile-application-in-young-to-midlife-adults-in-hong-kong 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07721181/escalada-de-la-dosis-de-radioterapia-para-el-manejo-no-quirurgico-del-cancer-colorrectal-localmente-recurrente-no-susceptible-de-reseccion-step-up 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07721181/radiotherapy-dose-escalation-for-non-operative-management-of-unresectable-locally-recurrent-rectal-cancer-step-up 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/un-ensayo-clinico-de-rsc-1255-para-el-tratamiento-de-pacientes-con-tumores-malignos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06098560/el-adn-tumoral-circulante-ctdna-como-biomarcador-predictivo-para-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-avanzado-o-localmente-avanzado-con-dmmr-msi-h 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmr-msi-h-colorectal-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-y-terapia-antiangiogenica-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-and-anti-angiogenesis-in-treating-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04041310/nous-209-vacuna-genetica-para-el-tratamiento-de-tumores-solidos-con-inestabilidad-de-microsatelites 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-genetic-vaccine-for-the-treatment-of-microsatellite-unstable-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06886282/radiomica-espacial-y-transcriptomica-para-el-descubrimiento-de-la-relacion-entre-el-cancer-de-colon-y-la-enfermedad-renal-cronica 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06886282/spatial-radiomics-and-transcriptomics-to-the-discovery-of-the-cross-link-between-colon-cancer-and-chronic-kidney-disease 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208371/tratamiento-local-frente-a-quimioterapia-paliativa-en-pacientes-con-cancer-colorrectal-y-10-o-mas-metastasis-hepaticas 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208371/localized-treatment-versus-palliative-chemotherapy-in-crc-patients-with-10-or-more-crlm 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06729736/implementacion-del-programa-eras-en-pacientes-con-cancer-colorrectal-un-estudio-de-un-solo-brazo 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06729736/implementation-of-the-eras-in-colorectal-cancer-patients-a-single-arm-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06930118/el-objetivo-de-este-estudio-es-evaluar-la-eficacia-y-la-seguridad-de-chidamide-regorafenib-en-combinacion-con-iparomlimab-y-tuvonralimab-para-el-tratamiento-del-cancer-colorrectal-avanzado-en-tercera 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06930118/the-aim-of-this-study-is-to-assess-the-efficacy-and-safety-of-chidamide-regorafenib-in-combination-with-iparomlimab-and-tuvonralimab-for-the-treatment-of-advanced-colorectal-cancer-in-third-line 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06414122/estimulacion-electromiositimuladora-de-frecuencia-media-modulada-en-todo-el-cuerpo-y-terapia-nutricional-en-pacientes-con-cancer-gastrointestinal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06414122/modulated-mid-frequency-whole-body-electromyostimulation-and-nutritional-therapy-in-gastrointestinal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04307901/seguridad-de-la-evaluacion-del-cancer-colorrectal-y-la-valoracion-tumoral-mediante-la-colonoscopia-con-capsula 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04307901/safety-of-colorectal-assessment-and-tumor-evaluation-by-colon-capsule-endoscopy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06827366/intervencion-sobre-el-estilo-de-vida-en-participantes-del-programa-frances-de-deteccion-del-cancer-colorrectal-life-screen 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06827366/lifestyle-intervention-among-participants-of-the-french-colorectal-cancer-screening-program-life-screen 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07036185/un-ensayo-clinico-de-kj015-en-pacientes-con-tumores-solidos-que-expresan-her2 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07036185/a-clinical-trail-of-kj015-in-patients-with-her2-expressing-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/radioterapia-neoadyuvante-combinada-con-nalirifox-y-adebrelimab-en-cancer-colorrectal-localmente-avanzado-pmmr-mss-un-ensayo-clinico-prospectivo-aleatorizado-de-fase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528937/aplicacion-de-la-reconstruccion-tridimensional-para-la-planificacion-preoperatoria-del-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528937/application-of-3d-reconstruction-for-preoperative-strategy-of-locally-advanced-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/anticuerpo-anti-pd-1-tras-quimiorradioterapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-pmmr-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/pd-1-antibody-following-preoperative-chemoradiotherapy-for-locally-advanced-pmmr-mss-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020468/terapia-neoadyuvante-nalirifox-para-el-cancer-colorrectal-localmente-avanzado-y-el-cancer-del-recto-superior 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020468/neoadjuvant-therapy-nalirifox-for-locally-advanced-colon-and-upper-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/imagen-pet-de-dos-vartumabs-en-pacientes-con-tumores-solidos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/estudio-piloto-de-los-cambios-en-la-densidad-mineral-osea-durante-la-inmunoterapia-anti-pd-1 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/pilot-study-of-bone-mineral-density-changes-during-anti-pd-1-immunotherapy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07095517/vias-de-senalizacion-factores-de-riesgo-y-moleculas-para-prevenir-los-tumores-colorrectales-de-inicio-temprano 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07095517/pathways-risk-factors-and-molecules-to-prevent-early-onset-colorectal-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06487377/ix001-terapia-con-celulas-t-modificadas-con-receptores-quimericos-tcr-t-en-el-tratamiento-del-cancer-de-pancreas-avanzado-y-del-cancer-colorrectal-inducido-por-mutaciones-en-el-gen-kras 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06487377/ix001-tcr-t-in-the-treatment-of-advanced-pancreatic-cancer-and-colorectal-cancer-induced-by-kras-mutations 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06332274/tislelizumab-en-pacientes-con-cancer-que-presentan-enfermedad-residual-molecular 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06332274/tislelizumab-in-cancer-patients-with-molecular-residual-disease 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05902520/terapia-celular-adoptiva-que-utiliza-linfocitos-infiltrantes-tumorales-cd8-especificos-del-cancer-en-pacientes-adultos-con-tumores-solidos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05902520/adoptive-cell-therapy-using-cancer-specific-cd8-tumor-infiltrating-lymphocytes-in-adult-patients-with-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05797077/terapia-de-mantenimiento-postoperatoria-para-metastasis-hepaticas-resecables-del-cancer-colorrectal-guiada-por-ctdna 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05410977/recoleccion-de-muestras-de-sangre-y-heces-para-detectar-cancer-colorrectal-o-neoplasia-avanzada-en-pacientes-con-sindrome-de-lynch 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05410977/collecting-blood-and-stool-samples-to-detect-colorectal-cancer-or-advanced-neoplasia-in-lynch-syndrome-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-mas-cetuximab-en-un-entorno-neoadyuvante-en-pacientes-con-cancer-de-colon-o-recto-superior-localizado-con-mutacion-braf 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706779/encorafenib-plus-cetuximab-in-a-neoadjuvant-setting-in-patients-with-braf-mutation-localised-colon-or-upper-rectum-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07046468/una-pildora-inteligente-para-medir-la-salud-intestinal-en-la-inflamacion-del-colon-y-el-cancer-de-colon 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07046468/smart-pill-for-measuring-gut-health-in-colon-inflammation-and-colon-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03957902/evaluacion-de-biomarcadores-directos-de-la-accion-del-acido-acetilsalicilico-para-desarrollar-una-terapia-de-quimioprevencion-de-precision-contra-el-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03957902/assessment-of-direct-biomarkers-of-aspirin-action-to-develop-a-precision-chemoprevention-therapy-of-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948539/evaluar-la-tolerabilidad-y-la-farmacocinetica-de-tqb2101-para-inyeccion-en-pacientes-con-tumores-malignos-avanzados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06948539/to-evaluate-the-tolerability-and-pharmacokinetics-of-tqb2101-for-injection-in-patients-with-advanced-malignant-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000474/caracterizacion-multiparametrica-de-los-canceres-colorrectales-metrad 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000474/multiparametric-characterization-of-colorectal-cancers-metrad 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403981/promocion-colaboracion-divulgacion-y-obtencion-de-resultados-optimos-en-la-atencion-de-pacientes-con-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403981/advocacy-partnership-outreach-and-yielding-optimized-care-for-oncology-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-en-combinacion-con-capeox-y-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-combined-with-capeox-celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06588166/pruebas-del-microbioma-para-el-cribado-del-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06588166/microbiome-testing-for-the-screening-of-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-en-combinacion-con-regorafenib-como-tratamiento-de-tercera-linea-en-pacientes-con-crlm-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-combined-with-regorafenib-as-a-third-line-treatment-in-patients-with-mss-crlm 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06717880/un-estudio-de-ibi363-en-combinacion-con-bevacizumab-o-furuitinib-en-sujetos-con-cancer-colorrectal-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06717880/a-study-of-ibi363-in-combination-with-bevacizumab-or-furuitinib-in-subjects-with-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-locally-advanced-anal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05398380/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion-investigacion-traslacional 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05398380/liver-transplantation-for-non-resectable-colorectal-liver-metastases-translational-research 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/caracteristicas-y-relevancia-clinica-de-la-microbiota-intestinal-en-pacientes-con-gammapatia-monoclonal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/tratamiento-del-cancer-de-recto-con-quimiorradioterapia-concurrente-a-largo-plazo-combinada-con-camrelizumab 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/treatment-of-rectal-cancer-with-long-term-concurrent-chemoradiotherapy-combined-with-camrelizumab 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-trastuzumab-quimioterapia-en-tumores-solidos-her2-cancer-colorrectal-y-cancer-de-mama 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-with-trastuzumab-chemotherapy-in-her2-solid-tumors-colorectal-and-breast-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04861558/eficacia-de-la-quimioterapia-intraperitoneal-hiperermica 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04861558/efficacy-of-hyperthermic-intraperitoneal-chemotherapy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/explorando-la-duracion-del-tratamiento-con-terapia-neoadyuvante-anti-pd-1-en-el-cancer-colorrectal-en-estadio-ii-iii-con-dmmr 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/exploring-the-treatment-duration-of-pd-1-neoadjuvant-therapy-in-stage-ii-iii-dmmr-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674422/estudio-gemcad-reveal-el-adn-tumoral-circulante-como-predictor-de-recurrencia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/gemcad-reveal-study-circulating-tumor-dna-as-a-predictor-of-relapse-in-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/ensayo-clinico-que-evalua-la-eficacia-de-capecitabina-mas-lenvatinib-en-pacientes-con-cancer-colorrectal-avanzado-refractario-a-irinotecan-oxaliplatino-y-fluoropirimidina 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/clinical-trial-evaluating-the-efficacy-of-capecitabine-plus-lenvatinib-in-patients-with-advanced-colorectal-cancer-refractory-to-irinotecan-oxaliplatin-and-fluoropyrimidine 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06516445/radioterapia-de-corta-duracion-seguida-de-camrelizumab-en-combinacion-con-fluzoparib-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/scrt-followed-by-camrelizumab-combined-with-fluzoparib-and-chemotherapy-as-neoadjuvant-therapy-for-larc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06930586/valor-pronostico-de-las-redes-neurometabolicas-en-el-ccrc-pvnm-ccrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06930586/prognostic-value-of-neurometabolic-networks-in-crc-pvnm-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090643/investigacion-sobre-la-implementacion-de-estrategias-para-aumentar-las-tasas-de-deteccion-del-cancer-colorrectal-en-grupos-de-bajos-ingresos-y-minorias-etnicas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06090643/implementation-research-to-increase-colorectal-cancer-screening-rates-among-low-income-and-ethnic-minority-groups 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405776/efecto-de-la-lidocaina-sobre-el-dolor-postoperatorio-y-la-supervivencia-a-largo-plazo-en-pacientes-geriatricos-sometidos-a-cirugia-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405776/effect-of-lidocaine-on-postoperative-pain-and-long-term-survival-in-elderly-patients-undergoing-colorectal-surgery 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06855849/un-estudio-de-fase-ii-abierto-de-un-solo-brazo-y-multicentrico-para-evaluar-la-eficacia-de-amivantamab-en-combinacion-con-folfiri-como-tratamiento-de-segunda-linea-en-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06855849/an-open-label-single-arm-multicenter-phase-ii-study-to-evaluate-the-efficacy-of-amivantamab-in-combination-with-folfiri-as-a-second-line-treatment-in-patients-with-ras-braf-wild-type-advanced 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04527861/resultados-oncologicos-de-la-cirugia-laparoscopica-convencional-frente-a-la-cirugia-laparoscopica-con-una-sola-incision-en-el-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04527861/oncologic-outcomes-of-single-incision-versus-conventional-laparoscopic-surgery-for-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07463690/diseno-y-evaluacion-de-un-modelo-de-alta-hospitalaria-invertida-para-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07463690/construction-and-evaluation-of-a-flipped-discharge-model-for-stomates-with-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06507371/radioterapia-de-curso-corto-que-preserva-los-ganglios-combinada-con-capox-y-tislelizumab-para-el-cancer-colorrectal-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06507371/node-sparing-short-course-radiation-combined-with-capox-and-tislelizumab-for-mss-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/trasplante-de-la-microbiota-intestinal-para-el-tratamiento-de-la-caquexia-tumoral-avanzada 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01239082/colonoscopia-frente-a-prueba-inmunoquimica-fecal-para-reducir-la-mortalidad-por-cancer-colorrectal-confirm 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01239082/colonoscopy-versus-fecal-immunochemical-test-in-reducing-mortality-from-colorectal-cancer-confirm 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07709429/ejercicio-de-qigong-para-mejorar-la-fuerza-muscular-y-la-calidad-de-vida-en-pacientes-con-cancer-colorrectal-que-reciben-quimioterapia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07709429/qigong-exercise-for-muscles-strength-and-quality-of-life-in-colorectal-cancer-patients-undergoing-chemotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03516708/se-anade-epacadostat-incb024360-a-la-quimiorradiacion-preoperatoria-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03516708/epacadostat-incb024360-added-to-preoperative-chemoradiation-in-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06616870/estudio-del-papel-predictivo-y-pronostico-de-las-variantes-farmacogeneticas-y-radiogenicas-en-la-respuesta-al-tratamiento-neoadyuvante-con-quimiorradiacion-en-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/study-of-the-predictive-and-prognostic-role-of-pharmacogenetic-and-radiogenic-variants-on-the-response-to-neoadjuvant-chemoradiation-therapy-in-patients-with-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-para-el-cancer-colorrectal-avanzado-con-pmmr-y-metastasis-hepaticas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-for-advanced-pmmr-colorectal-cancer-with-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-y-panitumumab-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-and-panitumumab-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/evaluacion-longitudinal-multimodal-de-la-respuesta-durante-el-tratamiento-neoadyuvante-del-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/longitudinal-multimodal-response-assessment-during-neoadjuvant-treatment-of-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/radioterapia-de-curso-corto-modificada-combinada-con-inmunoterapia-quimioterapia-y-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/modified-short-course-radiotherapy-combined-with-immunochemotherapy-and-targeted-therapy-as-first-line-treatment-for-mss-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195111/un-estudio-en-el-mundo-real-de-un-regimen-que-contiene-trifluridina-tipiracil-para-el-tratamiento-de-pacientes-con-mcrc-estudio-reflect 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195111/a-real-world-study-of-trifluridine-tipiracil-containing-regimen-for-the-treatment-of-patients-with-mcrc-reflect-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06654037/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-abemaciclib-al-tratamiento-quimioterapeutico-habitual-5-fluorouracilo-para-el-cancer-colorrectal-metastasico-y-refractario 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06654037/testing-the-addition-of-an-anti-cancer-drug-abemaciclib-to-the-usual-chemotherapy-treatment-5-fluorouracil-for-metastatic-refractory-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06958419/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-linfaticos-combinada-con-quimioterapia-bevacizumab-e-inhibidor-de-pd-1-en-cancer-colorrectal-metastasico-pmmr-mss-modifi-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958419/node-sparing-short-course-radiotherapy-plus-chemotherapy-bevacizumab-and-pd-1-inhibitor-in-metastatic-pmmr-mss-colorectal-cancer-modifi-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT01815359/icarus-quimioterapia-intraperitoneal-postoperatoria-epic-y-quimioterapia-intraperitoneal-hiperermica-hipec-tras-una-cirugia-citoreductora-optima-crs-para-neoplasias-del-apendice-colon-o-recto-con 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01815359/icarus-post-operative-intraperitoneal-chemotherapy-epic-and-hyperthermic-intraperitoneal-chemotherapy-hipec-after-optimal-cytoreductive-surgery-crs-for-neoplasms-of-the-appendix-colon-or-rectum-with 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04796818/una-exploracion-de-investigacion-imagen-por-difusion-ponderada-con-el-modelo-de-movimiento-incoherente-intravoxel-para-la-evaluacion-de-la-respuesta-al-tratamiento-de-las-metastasis-hepaticas-del 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04796818/an-investigational-scan-intravoxel-incoherent-motion-diffusion-weighted-imaging-for-the-evaluation-of-colorectal-cancer-liver-metastases-treatment-response 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07353268/estudio-de-fase-ib-ii-de-ql1706-fruquintinib-terapia-de-radiacion-concurrente-scrt-frente-a-la-terapia-estandar-de-tercera-linea-en-cancer-colorrectal-irresecable-con-metastasis-hepaticas-y-estado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07353268/phase-ib-ii-study-of-ql1706-fruquintinib-scrt-vs-standard-third-line-therapy-in-unresectable-liver-metastatic-pmmr-mss-colorectal-cancer-safety-tolerability-and-efficacy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06521827/el-papel-de-un-ciclo-corto-de-radioterapia-paliativa-en-el-cancer-de-recto-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/the-role-of-short-course-of-palliative-radiation-in-metastatic-cancer-rectum 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05884723/dieta-cetogenica-preoperatoria-para-la-reduccion-de-la-esteatosis-hepatica 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05884723/preoperative-ketogenic-diet-for-reduction-of-hepatic-steatosis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409805/vacuna-ymn-136-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-que-presentan-progresion-tras-el-tratamiento-en-tercera-linea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409805/ymn-136-vaccine-for-patients-with-liver-metastasis-of-colorectal-cancer-progressing-after-third-line-treatment 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/un-estudio-sobre-la-radioterapia-estereotactica-de-cuerpo-unico-sbrt-guiada-por-resonancia-magnetica-rm-en-pacientes-con-metastasis-hepaticas-procedentes-del-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/a-study-of-single-fraction-stereotactic-body-radiation-therapy-sbrt-guided-by-magnetic-resonance-imaging-mri-in-people-with-liver-metastasis-from-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07009145/ql1706-mas-bevacizumab-para-el-cancer-colorrectal-irresecable-o-metastasico-msi-h-dmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-h-dmmr-crc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-mas-anlotinib-o-ademas-en-combinacion-con-penpulimab-para-el-tratamiento-de-segunda-linea-del-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05229003/irinotecan-plus-anlotinib-or-further-in-combination-with-penpulimab-for-second-line-treatment-of-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05838768/estudio-de-hro761-en-monoterapia-o-en-combinacion-en-pacientes-con-cancer-que-presenten-alteraciones-especificas-en-el-adn-denominadas-inestabilidad-de-microsatelites-o-deficiencia-en-la-reparacion 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05838768/study-of-hro761-alone-or-in-combination-in-cancer-patients-with-specific-dna-alterations-called-microsatellite-instability-or-mismatch-repair-deficiency 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201194/acupuntura-holistica-para-pacientes-con-nauseas-inducidas-por-la-quimioterapia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05904665/estrategia-de-seguimiento-postoperatorio-guiada-por-la-metilacion-del-adn-tumoral-circulante-en-el-cancer-colorrectal-no-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05904665/circulating-tumor-dna-methylation-guided-postoperative-follow-up-strategy-for-non-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05250648/ensayo-clinico-sobre-la-administracion-de-hipec-con-mitomicina-c-en-metastasis-peritoneales-del-cancer-de-colon-gecop-mmc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/clinical-trial-on-hipec-with-mitomycin-c-in-colon-cancer-peritoneal-metastases-gecop-mmc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06788171/pulsar-en-combinacion-con-un-anticuerpo-anti-pd-1-y-quimioterapia-mas-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-ccrm 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06788171/pulsar-combined-with-pd-1-ab-and-chemotherapy-plus-bev-for-crlm 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/inmunoterapia-combinada-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-resistente-a-la-quimioterapia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/combination-immunotherapy-for-the-treatment-of-chemotherapy-refractory-metastatic-mss-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/estudio-de-jdq443-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/study-of-jdq443-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06580574/inhibidores-de-los-puntos-de-control-inmunitario-para-la-preservacion-de-organos-en-canceres-gastricos-o-de-colon-no-metastasicos-con-dmmr-msi-h 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmr-msi-h-gastric-or-colon-cancers 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04847063/respuesta-individual-al-tratamiento-con-quimioterapia-hipertermica-intraperitoneal-hipec-de-la-carcinomatosis-peritoneal-procedente-de-mesotelioma-peritoneal-o-proliferacion-mesotelial-atipica-o-de 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04847063/individual-response-to-hyperthermic-intraperitoneal-chemotherapy-hipec-treatment-of-peritoneal-carcinomatosis-from-peritoneal-mesothelioma-or-atypical-mesothelial-proliferation-or-from-ovarian 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/modelado-personalizado-de-xenoinjertos-derivados-del-paciente-ppdx-para-evaluar-la-respuesta-a-farmacos-en-un-huesped-compatible 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/personalized-patient-derived-xenograft-ppdx-modeling-to-test-drug-response-in-matching-host 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-para-la-prevencion-de-la-recurrencia-y-la-metastasis-en-pacientes-con-cancer-colorrectal-tras-la-cirugia-radical 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-for-prevention-of-recurrence-and-metastasis-of-colorectal-cancer-patients-following-radical-surgery 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07714447/eficacia-y-seguridad-de-la-terapia-combinada-con-tunlametinib-en-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treatment-of-second-line-and-above-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07260058/terapia-con-celulas-inmunitarias-para-tumores-solidos-avanzados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260058/immune-cell-therapy-for-advanced-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06493760/un-estudio-de-fase-ii-de-ssgj-707-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04329494/pipac-para-el-tratamiento-de-la-carcinomatosis-peritoneal-en-pacientes-con-cancer-de-ovario-utero-apendice-colon-o-estomago 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04329494/pipac-for-the-treatment-of-peritoneal-carcinomatosis-in-patients-with-ovarian-uterine-appendiceal-colorectal-or-gastric-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05425940/estudio-de-xl092-atezolizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05425940/study-of-xl092-atezolizumab-vs-regorafenib-in-participants-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/resistencia-primaria-y-adquirida-al-tratamiento-dirigido-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/primary-and-acquired-resistance-to-targeted-treatment-in-braf-v600e-mutated-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622550/un-estudio-clinico-multicentrico-de-un-solo-brazo-que-evalua-la-combinacion-de-fruquintinib-con-serplulimab-y-quimioterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/a-single-arm-multicenter-clinical-study-of-fruquintinib-combined-with-serplulimab-and-chemotherapy-as-first-line-treatment-for-patients-with-ras-braf-mutated-advanced-colorectal-cance 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337551/acetato-de-gossipol-folfiri-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-en-tp53-y-expresion-positiva-de-lrpprc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337551/gossypol-acetate-folfiri-bev-in-mcrc-with-tp53-mutant-and-lrpprc-positive 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/tratamiento-estandar-de-segunda-linea-tratamiento-secuencial-con-tas-102-y-bevacizumab-combinado-con-tratamiento-local-en-cancer-colorrectal-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/second-line-standard-treatment-sequential-tas-102-and-bevacizumab-combined-with-local-treatment-in-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06643793/evaluacion-del-liposoma-de-irinotecan-ii-en-combinacion-con-5-fu-lv-y-bevacizumab-para-el-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07061210/un-estudio-exploratorio-de-hrs-2189-en-combinacion-con-adebrelimab-y-bp102-para-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07061210/an-explorative-study-of-hrs-2189-combined-with-adebrelimab-and-bp102-for-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05970302/xelox-bevacizumab-tislelizumab-para-el-tratamiento-de-primera-linea-del-mcrc-con-mss-pmmr-y-mutacion-en-ras 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bev-tislelizumab-for-first-line-treatment-of-mss-pmmr-ras-mutated-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229846/un-estudio-clinico-de-fase-ii-de-un-solo-brazo-y-en-un-solo-centro-para-evaluar-aipalolitovorelizumab-ql1706-en-combinacion-con-bevacizumab-y-quimioterapia-estandar-como-tratamiento-de-primera-linea 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229846/a-single-arm-single-center-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-bevacizumab-and-standard-chemotherapy-as-first-line-treatment-for-mss-pmmr-metastatic-colorectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03941080/dinamica-del-microbioma-intestinal-en-el-cancer-colorrectal-metastasico-o-irresecable 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03941080/gut-microbiome-dynamics-in-metastasized-or-irresectable-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07416552/un-estudio-para-investigar-cea-prit-2-0-en-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07416552/a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-colorectal-cancer-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06130826/activacion-de-la-respuesta-inmune-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-o-del-cancer-de-mama-metastasico-con-niveles-elevados-de-cea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/immune-response-activation-for-the-treatment-of-unresectable-metastatic-colorectal-cancer-or-cea-positive-metastatic-breast-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06967155/un-estudio-de-irinotecan-con-dabrafenib-mas-trametinib-y-anti-egfr-en-la-segunda-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06967155/a-study-of-irinotecan-with-dabrafenib-plus-trametinib-and-anti-egfr-in-the-second-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/lyl273-for-patients-with-relapsed-or-refractory-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07591597/un-ensayo-clinico-multicentrico-de-fase-ib-ii-para-evaluar-la-eficacia-y-la-seguridad-de-la-terapia-combinada-concurrente-de-s-531011-mas-fruquintinib-o-s-531011-mas-fruquintinib-mas-pembrolizumab-en 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/a-multicenter-phase-ib-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-concurrent-combination-therapy-of-s-531011-plus-fruquintinib-or-s-531011-plus-fruquintinib-plus-pembrolizumab-in 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/un-estudio-de-seguridad-tolerabilidad-y-eficacia-de-nc410-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-irresecables-o-metastasicos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/a-safety-tolerability-and-efficacy-study-of-nc410-plus-pembrolizumab-in-participants-with-advanced-unresectable-or-metastatic-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-mas-bevacizumab-con-o-sin-atezolizumab-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-pmmr-e-ic-alto 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06733038/folfoxiri-plus-bevacizumab-with-or-without-atezolizumab-as-1st-line-treatment-of-pmmr-and-is-ic-high-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-en-combinacion-con-pemetrexed-para-el-tratamiento-de-tumores-solidos-metastasicos-con-delecion-de-mtap 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-in-combination-with-pemetrexed-for-the-treatment-of-metastatic-solid-tumors-with-mtap-deletion 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-en-el-cancer-colorrectal-avanzado-un-estudio-exploratorio 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-in-advanced-colorectal-cancer-an-exploratory-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284849/un-estudio-para-evaluar-la-eficacia-y-la-seguridad-de-la-quimioterapia-estandar-y-el-bevacizumab-con-o-sin-inca33890-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06269978/oxaliplatino-y-fluorouracilo-administrados-por-via-intraperitoneal-para-el-tratamiento-de-pacientes-con-metastasis-peritoneales-procedentes-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06269978/intraperitoneal-oxaliplatin-and-fluorouracil-for-the-treatment-of-patients-with-peritoneal-metastases-from-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06242067/tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06242067/second-line-treatment-of-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-de-cancer-colorrectal-metastasico-irresecable-a-resecable 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07718490/inmunoterapia-combinada-con-simvastatina-y-terapia-dirigida-y-quimioterapia-para-el-cancer-colorrectal-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07718490/immunotheray-combined-with-simvastatin-and-target-therapy-and-chemotharepy-for-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/un-ensayo-de-fase-i-iia-fih-que-evalua-la-viabilidad-de-la-administracion-de-inmunoterapia-basada-en-til-en-pacientes-con-crc-metastasico-y-cancer-de-pancreas 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/a-fih-phase-i-iia-trial-assessing-feasibility-of-administrations-of-til-based-immunotherapy-in-patients-with-metastatic-crc-and-pc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07720115/ensayo-de-fase-ii-de-s-531011-en-combinacion-con-radscopal-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07720115/phase-2-trial-of-s-531011-with-radscopal-in-previously-treated-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-en-combinacion-con-fianlimab-para-el-cancer-colorrectal-no-metastasico-que-puede-ser-extirpado-quirurgicamente 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-with-fianlimab-for-resectable-non-metastatic-colon-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/un-estudio-de-es104-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167448/a-study-of-es104-in-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07310537/viabilidad-del-analisis-del-adn-tumoral-circulante-ctdna-mediante-la-extraccion-automatizada-de-muestras-de-sangre-capilar 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310537/feasibility-of-circulating-tumour-dna-ctdna-analysis-using-automated-capillary-blood-sampling 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-un-estudio-para-obtener-mas-informacion-sobre-el-farmaco-de-estudio-denominado-pf-08634404-en-combinacion-con-quimioterapia-en-participantes-adultos-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/estudio-sobre-el-impacto-de-una-dieta-mediterranea-modificada-en-pacientes-con-cancer-colorrectal-que-reciben-tratamiento-oncologico-activo 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04603287/un-estudio-de-si-b001-un-anticuerpo-bispecifico-anti-egfr-her3-en-tumores-epiteliales-localmente-avanzados-o-metastasicos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04603287/a-study-of-si-b001-an-egfr-her3-bispecific-antibody-in-locally-advanced-or-metastatic-epithelial-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-alcestobart-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/ablacion-por-microondas-combinada-con-quimioterapia-para-metastasis-hepaticas-de-cancer-colorrectal-un-estudio-de-cohortes-multicentrico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/microwave-ablation-combined-with-chemotherapy-for-colorectal-liver-metastases-a-multicenter-cohort-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543744/un-estudio-comparativo-de-la-farmacocinetica-la-seguridad-y-la-inmunogenicidad-de-rph-030-y-vectibix-r-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-de-tipo-salvaje-como-terapia-de-primera 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/a-comparative-study-of-pharmacokinetics-safety-and-immunogenicity-of-rph-030-and-vectibix-r-in-patients-with-metastatic-colorectal-cancer-with-wild-type-ras-as-first-line-therapy-in-combination-with 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/estudio-de-eficacia-y-seguridad-de-tisotumab-vedotina-en-pacientes-con-tumores-solidos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/efficacy-and-safety-study-of-tisotumab-vedotin-for-patients-with-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06833866/ensayo-de-fase-i-de-una-terapia-basada-en-5-fluorouracilo-5fu-en-combinacion-con-hidroxitirosol-ht-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/phase-i-trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-hydroxytyrosol-ht-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/estudio-exploratorio-de-liposomas-de-irinotecan-en-la-terapia-de-mantenimiento-del-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/exploratory-study-of-irinotecan-liposomes-in-maintenance-therapy-of-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-mas-irinotecan-en-pacientes-con-cancer-colorrectal-metastasico-con-tipo-salvaje-de-neoras-en-terapia-de-tercera-linea 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-plus-irinotecan-in-patients-with-neoras-wild-type-metastatic-colorectal-cancer-in-third-line-therapy 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/un-estudio-multicentrico-de-fase-1b-2-con-adagrasib-cetuximab-y-cemiplimab-para-el-cancer-colorrectal-metastasico-que-presenta-mutaciones-kras-g12c 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/a-multicenter-phase-1b-2-study-of-adagrasib-cetuximab-and-cemiplimab-for-metastatic-colorectal-cancer-harboring-kras-g12c-mutations 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07587827/estudio-que-evalua-la-seguridad-la-viabilidad-y-la-eficacia-de-la-vacuna-odi-2001-una-inmunoterapia-personalizada-en-pacientes-con-cancer-colorrectal-metastasico-o-localmente-avanzado-o-cancer-de 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587827/study-evaluating-the-safety-feasibility-and-efficacy-of-odi-2001-vaccine-a-personnalized-immunotherapy-in-patients-with-metastatic-or-locally-advanced-colon-cancer-or-pancreatic-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/firma-de-aprendizaje-profundo-multimodal-para-la-evaluacion-de-la-respuesta-al-bevacizumab-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/multimodal-deep-learning-signature-for-evaluation-of-response-to-bevacizumab-in-patient-with-colorectal-cancer-liver-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02886104/comparacion-de-la-hepatectomia-y-la-ablacion-local-para-el-tratamiento-de-metastasis-hepaticas-sincronicas-y-metacronicas-resecables-del-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparison-of-hepatectomy-and-local-ablation-for-resectable-synchronous-and-metachronous-colorectal-liver-metastasis 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07653685/un-estudio-clinico-de-tqb2930-inyectable-y-quimioterapia-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/a-clinical-study-of-tqb2930-injection-and-chemotherapy-with-or-without-bevacizumab-in-the-treatment-of-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT02597348/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-tratados-con-quimioterapia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02597348/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases-treated-by-chemotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/ejercicio-fisico-postoperatorio-y-metastasis-hepatica-del-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/postoperative-exercise-training-and-colorectal-cancer-liver-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03635021/estudio-para-evaluar-la-eficacia-de-folfox-panitumumab-seguido-de-folfiri-bevacizumab-secuencia-1-frente-a-folfox-bevacizumab-seguido-de-folfiri-panitumumab-secuencia-2-en-pacientes-no-tratados-con 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03635021/study-to-evaluate-the-efficacy-of-folfox-panitumumab-followed-by-folfiri-bevacizumab-sequence-1-versus-folfox-bevacizumab-followed-by-folfiri-panitumumab-sequence-2-in-untreated-patients-with-wild 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/deteccion-de-metastasis-cerebrales-mediante-resonancia-magnetica-en-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/detection-of-brain-metastasis-by-mri-in-metastatic-colorectal-cancer-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07685236/un-estudio-de-exploracion-de-biomarcadores-para-predecir-la-localizacion-de-la-recurrencia-y-la-metastasis-en-el-cancer-colorrectal-estudio-probe 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/a-biomarker-exploration-study-for-predicting-localization-of-recurrence-and-metastasis-in-colorectal-cancer-probe-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04157322/marcadores-plasmaticos-de-5hmc-como-indicador-de-metastasis-peritoneal-en-cancer-colorrectal-apendicular 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/plasma-5hmc-signatures-as-a-marker-of-colorectal-appendiceal-peritoneal-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04867525/plataforma-de-registro-de-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04867525/registry-platform-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-en-combinacion-en-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-en-estadio-iv-resistente-al-tratamiento-y-en-otros-canceres-metastasicos-del 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-combination-in-stage-iv-refractory-pmmr-mss-crc-and-other-metastatic-gi-cancers 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/ensayo-clinico-de-fase-ii-de-cadonilimab-en-combinacion-con-agentes-antiangiogenicos-en-el-cancer-colorrectal-metastasico-dmmr-msi-h 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/phase-ii-clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmr-msi-h-crc 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04868877/estudio-de-fase-i-ii-que-evalua-mcla-129-un-anticuerpo-humano-bispecifico-anti-egfr-y-anti-c-met-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-y-otros-tumores-solidos-tanto-en 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/phase-1-2-study-evaluating-mcla-129-a-human-anti-egfr-anti-c-met-bispecific-antibody-in-advanced-nsclc-and-other-solid-tumors-alone-and-in-combination 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07702032/estudio-de-petosemtamab-mas-quimioterapia-frente-a-cetuximab-mas-quimioterapia-en-cancer-colorrectal-irresecable-o-metastasico-del-lado-izquierdo-con-ras-y-braf-de-tipo-salvaje 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07702032/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-plus-chemotherapy-in-ras-and-braf-wild-type-unresectable-or-metastatic-left-sided-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03326791/aspirina-en-metastasis-hepaticas-del-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirin-in-colorectal-cancer-liver-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04575922/nivolumab-ipilimumab-radioterapia-en-pacientes-con-mcrc-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04575922/nivolumab-ipilimumab-rt-in-mss-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258137/adn-circulante-para-mejorar-el-pronostico-de-los-pacientes-oncologicos-un-estudio-aleatorizado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04258137/circulating-dna-to-improve-outcome-of-oncology-patient-a-randomized-study 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06053996/radioesterilizacion-hepatopulmonar-combinada-con-inmunoterapia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06053996/hepatopulmonary-radio-sterilization-with-immunotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06840977/cancer-de-colon-en-pacientes-de-la-tercera-edad-dosis-baja 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06840977/colon-erderly-low-dose 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/estudio-de-inhibidores-de-ras-on-en-pacientes-con-tumores-solidos-gastrointestinales 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04729322/trasplante-de-microbiota-fecal-y-reintroduccion-de-la-terapia-anti-pd-1-pembrolizumab-o-nivolumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-en-pacientes-que-no-responden-a-la-terapia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04729322/fecal-microbiota-transplant-and-re-introduction-of-anti-pd-1-therapy-pembrolizumab-or-nivolumab-for-the-treatment-of-metastatic-colorectal-cancer-in-anti-pd-1-non-responders 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007728/iparolimab-tuvonralimab-en-combinacion-con-bevacizumab-y-capeox-como-terapia-de-conversion-para-metastasis-hepaticas-del-cancer-colorrectal 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007728/iparomlimab-tuvonralimab-combined-with-bevacizumab-and-capeox-as-conversion-therapy-for-colorectal-cancer-liver-metastasis 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04314401/banco-de-muestras-biologicas-del-programa-cancer-moonshot-del-instituto-nacional-del-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04314401/national-cancer-institute-cancer-moonshot-biobank 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05669430/un-estudio-de-la-monoterapia-con-gv20-0251-y-la-combinacion-de-gv20-0251-con-pembrolizumab-en-participantes-con-tumores-solidos-malignos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05669430/a-study-of-gv20-0251-monotherapy-and-gv20-0251-in-combination-with-pembrolizumab-in-participants-with-solid-tumor-malignancies 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07318805/un-estudio-para-evaluar-el-medicamento-pf-08032562-en-personas-con-tumores-solidos-avanzados-o-metastasicos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07318805/a-study-to-learn-about-the-study-medicine-called-pf-08032562-in-people-with-advanced-or-metastatic-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05334069/recopilacion-de-muestras-de-sangre-de-pacientes-con-y-sin-cancer-para-evaluar-pruebas-de-deteccion-temprana-del-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05334069/collecting-blood-samples-from-patients-with-and-without-cancer-to-evaluate-tests-for-early-cancer-detection 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/el-uso-del-anticuerpo-monoclonal-marcado-con-cobre-64-cu-64-anti-cea-m5a-en-la-tomografia-por-emision-de-positrones-pet-para-el-diagnostico-de-pacientes-con-cancer-cea-positivo 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/copper-cu-64-anti-cea-monoclonal-antibody-m5a-pet-in-diagnosing-patients-with-cea-positive-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07169734/un-estudio-para-investigar-ale-p03-como-terapia-unica-en-pacientes-adultos-con-tumores-solidos-avanzados-o-metastasicos-cldn1-seleccionados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07169734/a-study-to-investigate-ale-p03-as-monotherapy-in-adult-patients-with-selected-advanced-or-metastatic-cldn1-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636785/un-estudio-de-fase-1-y-2-de-vmd-102-en-carcinoma-hepatocelular-y-otros-tumores-solidos 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636785/a-phase-1-and-2-study-of-vmd-102-in-hepatocellular-carcinoma-and-other-solid-tumors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02568267/estudio-basket-de-entrectinib-rxdx-101-para-el-tratamiento-de-pacientes-con-tumores-solidos-que-presentan-reordenamientos-fusiones-en-los-genes-ntrk-1-2-3-trk-a-b-c-ros1-o-alk 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT02568267/basket-study-of-entrectinib-rxdx-101-for-the-treatment-of-patients-with-solid-tumors-harboring-ntrk-1-2-3-trk-a-b-c-ros1-or-alk-gene-rearrangements-fusions 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07345273/informe-de-los-depositos-tumorales-en-el-cancer-colorrectal-mediante-radiologia-y-patologia 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345273/reporting-of-tumour-deposits-in-colorectal-cancer-by-radiology-and-pathology 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06342401/deteccion-temprana-del-cancer-colorrectal-en-pacientes-jovenes 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/early-onset-colorectal-cancer-detection 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07348211/primer-estudio-en-humanos-de-sim0610-en-tumores-solidos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07348211/first-in-human-study-of-sim0610-in-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614751/dat-2645-un-inhibidor-de-parg-como-monoterapia-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-alteraciones-de-perdida-de-funcion-en-brca1-2-y-o-otros-defectos-en-la-via-de 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/a-parg-inhibitor-dat-2645-monotherapy-in-patients-with-advanced-metastatic-solid-tumors-harboring-brca1-2-loss-of-function-alterations-and-or-other-defects-in-the-ddr-pathway 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-en-combinacion-con-adebrelimab-y-radioterapia-en-dosis-altas-y-bajas-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mss-que-ha-progresado-tras-tratamientos-previos-segunda 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-combined-with-adebrelimab-and-high-and-low-dose-radiotherapy-in-the-treatment-of-second-line-and-above-failure-mss-metastatic-colorectal-cancer 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combinacion-de-spartalizumab-mdcf-y-radioterapia-en-pacientes-con-carcinoma-anal-de-celulas-escamosas-metastasico 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combination-of-spartalizumab-mdcf-and-radiotherapy-in-patients-with-metastatic-squamous-cell-anal-carcinoma 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134205/estudio-de-jmt101-en-combinacion-con-irinotecan-como-tratamiento-en-3a-linea-en-el-cancer-colorrectal-metastasico 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134205/the-study-of-jmt101-combined-with-irinotecan-as-a-3rd-line-treatment-in-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06428409/un-estudio-clinico-de-mk-2870-solo-o-en-combinacion-con-otros-tratamientos-para-el-tratamiento-de-canceres-gastrointestinales-mk-9999-02a 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06428409/a-clinical-study-of-mk-2870-alone-or-with-other-treatments-to-treat-gastrointestinal-cancers-mk-9999-02a 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT03228667/quilt-3-055-un-estudio-sobre-la-combinacion-de-inmunoterapias-en-pacientes-que-previamente-han-recibido-tratamiento-con-inhibidores-de-puntos-de-control-inmunitario 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT03228667/quilt-3-055-a-study-of-combination-immunotherapies-in-patients-who-have-previously-received-treatment-with-immune-checkpoint-inhibitors 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361575/estudio-que-compara-la-calidad-de-la-limpieza-del-colon-con-una-dieta-preestablecida-de-bajo-contenido-en-residuos-lrd-frente-a-una-dieta-guiada-pog 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361575/study-comparing-the-quality-of-colon-cleanliness-with-prepackaged-lrd-low-residue-diet-vs-guided-pog 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-tercera-linea-o-posterior-en-pacientes-con-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-plus-bevacizumab-as-a-third-line-or-beyond-therapy-in-mcrc-patients 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06451497/este-es-un-ensayo-de-fase-i-de-zm008-un-anticuerpo-anti-llt1-que-se-utiliza-como-agente-unico-seguido-de-un-tratamiento-combinado-con-toripalimab-en-pacientes-con-tumores-solidos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06451497/this-is-a-phase-1-trial-of-zm008-an-anti-llt1-antibody-used-as-single-agent-followed-by-combination-treatment-with-toripalimab-in-patients-with-advanced-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/cancer-colorrectal-en-estadio-ii-iii-con-recurrencia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/stage-ii-iii-colorectal-cancer-recurrence 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06780787/folfox-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-de-recto-localizado-antes-de-la-cirugia 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06780787/folfox-botensilimab-and-balstilimab-for-the-treatment-of-localized-rectal-cancer-before-surgery 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07376707/un-estudio-de-fase-i-de-tgi-5-como-monoterapia-y-en-combinacion-con-nivolumab-en-sujetos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT07376707/a-phase-1-study-of-tgi-5-as-monotherapy-and-in-combination-with-nivolumab-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764771/un-estudio-de-bms-986488-como-terapia-unica-y-en-combinacion-en-participantes-con-tumores-malignos-avanzados 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764771/a-study-of-bms-986488-as-monotherapy-and-combination-therapy-in-participants-with-advanced-malignant-tumors 2026-07-30 weekly 0.7 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195670/estudio-clinico-de-radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-sintilimab-frente-a-bevacizumab-mas-capecitabina-como-tratamiento-de-primera-linea-en-pacientes-con-mcrc-avanzado 2026-07-30 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195670/clinical-study-of-short-course-radiotherapy-followed-by-fruquintinib-plus-sintilimab-vs-bevacizumab-plus-capecitabine-as-first-line-treatment-in-advanced-mcrc 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2811/survival-outcomes-in-pod1um-303-interaact-2-a-phase-iii-study-of-retifanlimab-plus-carboplatin-paclitaxel-in-first-line-advanced-squamous-anal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2805/ubc9-and-pi3k-expression-in-colorectal-cancer-possible-prognostic-role 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2780/la-apigenina-7-glucosido-reprograma-el-metabolismo-tumoral-y-mejora-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-a-traves-de-dlx5 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2780/apigenin-7-glucoside-reprograms-tumor-metabolism-and-enhances-immunotherapy-efficacy-in-colorectal-cancer-via-dlx5 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2769/transportador-de-glucosa-1-en-la-salud-y-la-enfermedad 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2769/glucose-transporter-1-in-health-and-disease 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2764/nanoplataforma-probiotica-modificada-geneticamente-para-la-terapia-del-cancer-colorrectal-mediante-ultrasonido-que-permite-la-administracion-dirigida-la-modulacion-inmune-y-la-inhibicion-de-la 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2764/genetically-engineered-probiotic-nanoplatform-for-ultrasound-enhanced-colorectal-cancer-therapy-via-targeted-delivery-immune-modulation-and-anti-angiogenesis 2026-07-26 monthly 0.5 https://crcwarriors.org/articulo/2727/biomarcadores-multiomicos-de-la-respuesta-al-tratamiento-neoadyuvante-en-el-cancer-de-recto-una-revision-narrativa 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2727/multi-omic-biomarkers-of-neoadjuvant-treatment-response-in-rectal-cancer-a-narrative-review 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2720/terapia-neoadyuvante-total-frente-a-quimiorradioterapia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-una-revision-sistematica-y-metaanalisis-de-los-resultados-a-largo-plazo 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2720/total-neoadjuvant-therapy-versus-standard-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer-a-systematic-review-and-meta-analysis-of-long-term-outcomes 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2715/valor-pronostico-y-perfil-transcriptomico-espacial-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-sincronicas-de-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2715/prognostic-value-and-spatial-transcriptomic-landscape-of-histopathological-growth-patterns-in-synchronous-colorectal-liver-metastases 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2709/aplicaciones-del-aprendizaje-profundo-en-el-tratamiento-del-cancer-prediccion-base-de-investigacion-exhaustiva-para-una-revision-sistematica-y-un-metaanalisis 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2709/deep-learning-applications-in-cancer-treatment-prediction-comprehensive-research-foundation-for-systematic-review-and-meta-analysis 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2658/6ppdq-favorece-la-progresion-maligna-del-cancer-colorrectal-al-potenciar-la-senalizacion-de-egf-egfr 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2658/6ppdq-promotes-the-malignant-progression-of-colorectal-cancer-via-enhancing-egf-egfr-signaling 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2655/dos-lineas-celulares-dos-historias-caracterizacion-de-la-eficacia-diferencial-de-los-farmacos-de-molecula-pequena-cediranib-y-nu-7441-en-el-cancer-colorrectal-primario-frente-al-metastasico 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2655/a-tale-of-two-cell-lines-characterization-of-differential-efficacy-of-small-molecule-drugs-cediranib-and-nu-7441-on-primary-versus-metastatic-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2639/larotrectinib-en-el-tratamiento-adyuvante-y-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-fusion-de-ntrk 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2639/larotrectinib-in-adjuvant-and-first-line-treatment-for-metastatic-ntrk-fusion-colon-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2631/evaluacion-mediante-resonancia-magnetica-con-difusion-y-secuencias-en-fase-cest-mri-del-cancer-colorrectal-localmente-avanzado-con-pmmr-para-predecir-el-estado-de-activacion-inmune-tras-la 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2631/cest-mri-assessment-of-locally-advanced-pmmr-rectal-cancer-for-prediction-of-immune-activation-status-following-radiotherapy 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2497/el-anticuerpo-anti-tigit-30-278-igg1-rmd-con-una-fraccion-cristalizable-fc-mejorada-amplifica-la-inmunidad-antitumoral-mediante-la-activacion-de-las-celulas-efectoras-y-presenta-una-accion-sinergica 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2497/fc-enhanced-anti-tigit-antibody-30-278-igg1-rmd-amplifies-antitumor-immunity-through-effector-cell-activation-and-synergizes-with-pd-1-blockade 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2495/descifrando-los-mecanismos-funcionales-de-eif3f-en-los-tumores-y-explorando-terapias-dirigidas 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2495/deciphering-the-functional-mechanisms-of-eif3f-in-tumors-and-exploring-targeted-therapies 2026-07-23 monthly 0.5 https://crcwarriors.org/articulo/2420/la-cefarantina-induce-la-muerte-celular-inmunogenica-en-tumores-solidos-al-suprimir-la-expresion-de-la-poli-adp-ribosa-polimerasa-1-mediada-por-la-proteina-quinasa-c-zeta-y-presenta-una-accion 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2420/cepharanthine-triggers-immunogenic-cell-death-in-solid-tumors-by-suppressing-protein-kinase-c-zeta-mediated-poly-adp-ribose-polymerase-1-expression-and-synergizes-with-immunotherapy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2405/eficacia-y-seguridad-comparativas-de-los-tratamientos-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-una-revision-sistematica-y-un-metaanalisis-de-red 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2405/comparative-efficacy-and-safety-of-first-line-treatments-for-ras-wild-type-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-mas-bevacizumab-en-tumores-solidos-metastasicos-con-amplificacion-de-egfr-resultados-del-estudio-kosmos-i-ii-que-evalua-la-terapia-guiada-por-el-perfilado-molecular-en-canceres-avanzados 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-plus-bevacizumab-in-egfr-amplified-metastatic-solid-tumors-results-from-the-kosmos-i-ii-study-of-molecular-profiling-guided-therapy-in-advanced-cancers 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2393/diferencias-raciales-y-etnicas-en-los-resultados-del-cribado-del-cancer-de-prostata-en-los-estados-unidos-un-analisis-secundario-del-ensayo-sobre-el-cancer-de-prostata-pulmon-colon-y-ovario 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2393/racial-and-ethnic-differences-in-prostate-cancer-screening-outcomes-in-the-united-states-a-secondary-analysis-of-the-prostate-lung-colorectal-and-ovarian-cancer-trial 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2389/inmunoterapia-y-toma-de-decisiones-quirurgicas-en-el-cancer-colorrectal-asociado-al-sindrome-de-lynch-implicaciones-para-el-manejo-personalizado-y-la-revision-de-las-guias-clinicas 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2389/immunotherapy-and-surgical-decision-making-in-lynch-syndrome-associated-colorectal-cancer-implications-for-personalized-management-and-guideline-revision 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2380/terapia-dirigida-a-braf-en-tumores-no-melanoma-con-mutacion-braf-una-revision-sistematica-de-la-eficacia-que-es-amplia-pero-modulada-segun-el-tipo-histologico 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2380/braf-targeted-therapy-in-non-melanomatous-braf-mutant-tumours-a-systematic-review-of-broad-but-histology-modulated-efficacy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-la-integracion-de-aprendizaje-profundo-y-metodos-estadisticos-revela-patrones-espaciales-del-estroma-y-del-sistema-inmunitario-en-el-cancer-colorrectal-agresivo 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-deep-learning-statistical-integration-reveals-spatial-stromal-and-immune-signatures-of-aggressive-colon-cancer 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2337/impacto-de-la-certificacion-del-oncologo-medico-en-los-resultados-de-supervivencia-en-el-cancer-colorrectal-metastasico-evidencia-del-estudio-observacional-scrum-japan-monstar-screen 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2337/impact-of-medical-oncologist-certification-on-survival-outcomes-in-metastatic-colorectal-cancer-evidence-from-the-scrum-japan-monstar-screen-observational-study 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2300/un-estudio-aleatorizado-que-compara-encorafenib-cetuximab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-cancer-colorrectal-con-mutacion-braf-v600e-cohorte-3-del-estudio-breakwater 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2300/a-randomised-study-of-encorafenib-cetuximab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-in-braf-v600e-mutant-colorectal-cancer-breakwater-cohort-3 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2286/secuenciacion-rapida-de-proxima-generacion-in-situ-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2286/rapid-on-site-next-generation-sequencing-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2250/caracterizacion-espectroscopica-raman-de-los-cambios-proteicos-inducidos-por-el-5-fluorouracilo-en-celulas-de-cancer-de-colon 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2250/raman-spectroscopic-characterization-of-protein-changes-induced-by-5-fluorouracil-in-colon-cancer-cells 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-en-combinacion-con-3-metiladenina-para-el-tratamiento-del-cancer-de-pancreas-con-mutacion-kras-g12c-y-sus-mecanismos-subyacentes 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-combined-with-3-methyladenine-for-the-treatment-of-kras-g12c-mutant-pancreatic-cancer-and-its-underlying-mechanisms 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2212/metastasis-hepaticas-de-cancer-colorrectal-estrategias-de-imagen-para-el-diagnostico-la-planificacion-del-tratamiento-local-y-la-evaluacion-de-la-respuesta-al-tratamiento-sistemico 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2212/colorectal-liver-metastases-imaging-strategies-for-diagnosis-local-treatment-planning-and-systemic-treatment-response 2026-07-17 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-07-16 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-07-11 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-07-11 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/1498/una-plataforma-nano-basada-en-manganeso-que-aprovecha-los-efectos-quimiodynammaticos-y-adjutivos-para-la-vacunacion-in-situ-contra-el-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/1498/a-manganese-based-nanoplatform-leveraging-chemodynamic-and-adjuvant-effects-for-in-situ-vaccination-against-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/1290/entendimiento-actual-y-manejo-de-la-metastasis-cerebral-del-cancer-colorrectal-una-revision 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/1290/current-understanding-and-management-of-brain-metastasis-from-colorectal-cancer-a-review 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2809/spatial-transcriptomics-differences-of-histopathological-growth-patterns-in-colorectal-cancer-liver-metastases 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2808/the-multifaceted-role-of-socs3-in-colorectal-cancer-molecular-mechanisms-and-clinical-implications 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-a-randomized-study-of-mfolfox6-bevacizumab-atezolizumab-or-atezolizumab-alone-as-first-line-treatment-of-deficient-dna-mismatch-repair-metastatic-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2806/kras-mutations-reprogram-rna-m6a-modifications-to-drive-cd73-dependent-immune-evasion-in-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2800/rechallenge-therapy-new-dimensions-in-cancer-therapy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2799/single-cell-and-spatial-transcriptomic-landscapes-reveal-pigt-as-a-pivotal-regulator-of-immunometabolic-remodeling-in-colorectal-cancer-liver-metastasis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2797/immune-cytolytic-activity-correlates-with-tumor-microenvironmental-aberrations-in-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2796/female-oncofertility-in-colorectal-cancer-reproductive-uncertainties-and-potential-benefits-of-immunotherapy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2795/el-estado-de-p53-y-p21-influye-en-la-respuesta-celular-a-la-metformina-en-las-celulas-de-cancer-colorrectal-hct116-con-mutacion-en-el-gen-kras 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2795/p53-and-p21-status-influences-cellular-response-to-metformin-in-kras-mutant-hct116-colorectal-cancer-cells 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2793/molecular-plasticity-of-lama3-across-the-disease-spectrum-pathogenic-mechanisms-and-clinical-translation 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2779/impacto-en-la-supervivencia-de-los-eventos-adversos-graves-relacionados-con-la-inmunoterapia-en-los-canceres-digestivos-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2779/impact-on-survival-of-severe-immuno-related-adverse-events-in-deficient-mismatch-repair-microsatellite-instable-high-digestive-cancers-treated-with-immunotherapy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2771/inmunoterapia-en-el-cancer-colorrectal-asociado-a-la-deficiencia-constitucional-del-sistema-de-reparacion-de-errores-de-emparejamiento-cmmrd-en-pacientes-pediatricos-informe-de-un-caso-de-una 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2771/immunotherapy-in-pediatric-constitutional-mismatch-repair-deficiency-cmmrd-associated-colorectal-cancer-report-of-a-rare-variant-and-recommendations-for-screening 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-en-combinacion-con-nivolumab-para-el-tratamiento-del-cancer-colorrectal-con-microsatelites-estables-un-ensayo-de-fase-1-2 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-cancer-a-phase-1-2-trial 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-es-un-objetivo-sintal-letal-en-el-cancer-colorrectal-con-mutacion-en-pik3ca 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-is-a-synthetic-lethal-target-in-pik3ca-mutant-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2766/panorama-genomico-y-molecular-del-cancer-colorrectal-de-inicio-temprano-nuevos-conocimientos-e-implicaciones-clinicas-una-revision-sistematica 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2766/genomic-and-molecular-landscape-of-early-onset-colorectal-cancer-emerging-insights-and-clinical-implications-a-systematic-review 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2765/remodelacion-inmune-sistemica-tras-la-reseccion-curativa-r0-de-metastasis-hepaticas-de-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2765/systemic-immune-remodeling-following-curative-r0-resection-of-colorectal-liver-metastases 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-en-combinacion-con-bevacizumab-y-quimioterapia-como-terapia-de-segunda-linea-para-el-adenocarcinoma-colorrectal-avanzado-el-ensayo-de-fase-ii-defiance 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-as-second-line-therapy-for-advanced-colorectal-adenocarcinoma-the-phase-ii-defiance-trial 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2761/resultados-de-supervivencia-y-factores-pronosticos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-en-primera-linea-con-mfolfoxiri-mas-bevacizumab-un-estudio-observacional-en-vietnam 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2761/survival-outcomes-and-prognostic-factors-in-patients-with-metastatic-colorectal-cancer-treated-first-line-mfolfoxiri-plus-bevacizumab-a-real-world-study-in-vietnam 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2760/caracteristicas-de-la-microbiota-intestinal-en-el-cancer-colorrectal-con-diferentes-estados-de-inestabilidad-de-microsatelites 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2760/the-characteristics-of-gut-microbiota-in-colorectal-cancer-with-different-microsatellite-states 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2759/nueva-estrategia-de-tratamiento-y-lineas-de-investigacion-futuras-para-el-cancer-con-mutacion-en-el-gen-braf 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2759/new-treatment-strategy-and-future-research-direction-for-braf-mutated-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2758/la-inhibicion-de-kras-g12d-reprograma-el-microambiente-inmunosupresor-inducido-por-el-tumor-y-potencia-la-inmunidad-antitumoral-mediada-por-las-celulas-nk 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2758/kras-g12d-inhibition-reprograms-the-tumor-induced-immunosuppressive-environment-and-enhances-nk-cell-mediated-antitumor-immunity 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2757/el-potencial-terapeutico-de-los-conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avanzado-una-revision-sistematica-y-metaanalisis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2757/the-therapeutic-potential-of-antibody-drug-conjugates-in-advanced-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2756/revision-sistematica-y-comparacion-indirecta-ajustada-de-los-inhibidores-de-los-puntos-de-control-inmunitario-en-primera-linea-para-el-cancer-colorrectal-metastasico 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2756/systematic-review-and-adjusted-indirect-comparison-of-first-line-immune-checkpoint-inhibitors-in-metastatic-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2755/un-dihidrofenantreno-derivado-de-pholidota-chinensis-actua-como-un-componente-bioactivo-que-induce-la-ferroptosis-mediada-por-gpx4-en-el-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2755/a-pholidota-chinensis-derived-dihydrophenanthrene-acts-as-a-bioactive-constituent-to-trigger-gpx4-mediated-ferroptosis-in-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-mas-pembrolizumab-en-pacientes-con-cancer-colorrectal-o-gastrico-metastasico-con-inestabilidad-microsatelital-no-alta-un-estudio-multicentrico-de-fase-ib-iia 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-plus-pembrolizumab-in-patients-with-non-microsatellite-instability-high-metastatic-colorectal-or-gastric-cancer-a-multicenter-phase-ib-iia-study 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2751/evaluacion-in-vitro-e-in-silico-del-potencial-antitumoral-del-extracto-etanolico-de-las-semillas-de-bryonia-laciniosa-contra-el-cancer-colorrectal-y-el-cancer-hepatocelular 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2751/in-vitro-and-in-silico-evaluation-of-the-anticancer-potential-of-ethanolic-seed-extract-of-bryonia-laciniosa-against-colorectal-and-hepatocellular-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2750/el-contexto-tisular-determina-diferentes-resultados-premalignos-en-un-modelo-transgenico-de-raton-pik3ca-mutante-hpv16-e6-e7 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2750/tissue-context-shapes-distinct-premalignant-outcomes-in-an-hpv16-e6-e7-mutant-pik3ca-transgenic-mouse-model 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2749/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avances-desafios-y-perspectivas 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2749/antibody-drug-conjugates-in-colorectal-cancer-advances-challenges-and-prospectives 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2745/aspirina-como-terapia-adyuvante-para-el-cancer-colorrectal-con-tumores-con-mutacion-en-pik3ca-y-sobreexpresion-de-cox-2-el-estudio-de-investigacion-traslacional-ascolt-y-metaanalisis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2745/adjuvant-aspirin-for-colorectal-cancer-with-pik3ca-mutated-and-cox-2-overexpressed-tumours-the-ascolt-translational-research-study-and-meta-analysis 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2744/eficacia-y-seguridad-a-corto-plazo-de-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-del-desajuste 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2744/short-term-efficacy-and-safety-of-neoadjuvant-immunotherapy-for-locally-advanced-colon-cancer-with-deficient-mismatch-repair 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2743/cancer-colorrectal-metastasico-diagnosticado-antes-de-los-35-anos-un-subgrupo-distinto-de-enfermedad-de-inicio-temprano 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2743/metastatic-colorectal-cancer-diagnosed-before-age-35-a-distinct-subset-of-early-onset-disease 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2742/relevancia-pronostica-de-los-margenes-quirurgicos-segun-el-estado-de-kras-y-braf-en-las-metastasis-hepaticas-del-cancer-colorrectal-grupo-colaborativo-braf-kras-livermet 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2742/prognostic-relevance-of-surgical-margins-according-to-kras-and-braf-status-in-colorectal-liver-metastases-braf-kras-livermet-collaborative-group 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2739/tratamiento-del-cancer-de-recto-localizado-en-los-paises-nordicos-comparacion-de-las-guias-nordicas-con-las-guias-holandesas-de-la-esmo-y-de-la-nccn 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2739/treatment-of-localized-rectal-cancer-in-the-nordic-countries-comparison-of-nordic-to-dutch-esmo-and-nccn-guidelines 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2738/patrones-de-progresion-y-supervivencia-en-pacientes-con-cancer-colorrectal-metastasico-dmmr-msi-h-tratados-con-inmunoterapia 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2738/patterns-of-progression-and-survival-in-patients-with-mismatch-repair-deficient-microsatellite-instability-high-metastatic-colorectal-cancer-treated-with-immunotherapy 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2737/primer-caso-descrito-de-mutaciones-duales-de-resistencia-kras-y96c-y96s-detectadas-mediante-biopsia-liquida-en-un-cancer-colorrectal-metastasico-con-mutacion-kras-g12c 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2737/first-report-of-dual-kras-y96c-y96s-resistance-mutations-detected-by-liquid-biopsy-in-kras-g12c-mutant-metastatic-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2736/inmunoterapia-de-primera-linea-frente-a-quimioterapia-en-el-cancer-colorrectal-metastasico-con-msi-h-dmmr-una-revision-sistematica-y-un-metaanalisis-de-estudios-de-fase-iii 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2736/first-line-immunotherapy-versus-chemotherapy-in-msi-h-dmmr-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis-of-phase-iii-studies 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2732/caracteristicas-tumorales-y-factores-predictivos-de-supervivencia-en-pacientes-con-cancer-colorrectal-experiencia-en-un-unico-centro-en-el-libano 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2732/tumor-characteristics-and-survival-predictors-in-patients-with-colorectal-cancer-a-lebanese-single-center-experience 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2723/evolucion-de-la-resistencia-a-la-inmunoterapia-mediada-por-macrofagos-de-la-cavidad-spp1-en-la-metastasis-peritoneal-del-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2723/evolution-of-spp1-cavity-macrophage-mediated-immunotherapy-resistance-in-peritoneal-metastasis-of-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2722/estudio-de-fase-i-de-escalada-de-dosis-que-combina-la-quimioembolizacion-con-microesferas-de-irinotecan-y-la-radioembolizacion-con-microesferas-de-vidrio-de-itrio-90-en-metastasis-hepaticas-de-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2722/phase-i-dose-escalation-study-combining-irinotecan-loaded-drug-eluting-bead-chemoembolization-with-yttrium-90-glass-microspheres-radioembolization-in-colorectal-liver-metastases-debir-90-y 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2721/la-terapia-con-celulas-car-t-dirigidas-contra-gcc-no-protegidas-demuestra-una-eficacia-significativa-en-pacientes-con-cancer-colorrectal-avanzado 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2721/non-armored-gcc-targeting-car-t-cell-therapy-demonstrates-significant-efficacy-in-patients-with-advanced-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2719/prediccion-temprana-de-la-enfermedad-residual-minima-en-el-cancer-colorrectal-mediante-el-analisis-del-estado-de-metilacion-de-septin9-en-el-adn-tumoral-circulante 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2719/early-prediction-of-minimal-residual-disease-in-colorectal-cancer-via-septin9-methylation-status-in-circulating-tumor-dna 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2718/desde-la-fermentacion-hasta-los-farmabioticos-ingenieria-de-lactobacillus-derivado-del-kefir-para-una-inmunoterapia-intratumoral-dirigida-en-el-cancer-colorrectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2718/from-fermentation-to-pharmabiotics-engineering-kefir-derived-lactobacillus-for-targeted-intratumoral-immunotherapy-in-colorectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2717/dirigirse-al-ecosistema-espacial-metabolico-inmune-en-las-metastasis-hepaticas-del-cancer-colorrectal-estrategias-farmacologicas-y-el-paradigma-de-interrumpir-normalizar-restablecer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2717/targeting-the-spatial-metabolic-immune-ecosystem-in-colorectal-cancer-liver-metastasis-pharmacological-strategies-and-the-break-normalize-reset-paradigm 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2714/el-adn-tumoral-circulante-para-predecir-el-riesgo-de-tromboembolia-venosa-en-el-cancer-de-recto-localmente-avanzado 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2714/circulating-tumor-dna-to-predict-the-risk-of-venous-thromboembolism-in-locally-advanced-rectal-cancer 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2710/quimiocirugia-neoadyuvante-con-dosis-escaladas-frente-a-la-quimiocirugia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-resultados-a-9-anos-de-un-ensayo-aleatorizado-de-fase-2 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2710/dose-escalated-versus-standard-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer-9-year-results-of-a-randomized-phase-2-trial 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2708/alteraciones-del-genoma-mitocondrial-en-el-cancer-desde-mutaciones-y-epigenetica-hasta-terapias-dirigidas 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2708/mitochondrial-genome-alterations-in-cancer-from-mutations-and-epigenetics-to-targeted-therapiesack 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2705/oncologia-de-precision-de-ultima-generacion-en-el-cancer-colorrectal-con-estabilidad-en-los-microsatelites-enfoque-integrado-que-va-mas-alla-de-ras-y-raf 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2705/next-generation-precision-oncology-in-microsatellite-stable-colorectal-cancer-integrated-targeting-beyond-ras-and-raf 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2702/respuesta-clinica-completa-a-serplulimab-mas-bevacizumab-y-quimioterapia-en-adenocarcinoma-sigmoide-metastasico-mss-kras-mutado-informe-de-un-caso-y-revision-de-la-literatura 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2702/clinical-complete-response-to-serplulimab-plus-bevacizumab-and-chemotherapy-in-mss-kras-mutant-metastatic-sigmoid-colon-adenocarcinoma-a-case-report-and-literature-review 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2700/el-kras-mutado-suprime-la-deteccion-del-adn-al-remodelar-la-tension-de-la-membrana-para-eliminar-el-adn-tumoral-extracelular 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2700/mutant-kras-suppresses-dna-sensing-by-remodeling-membrane-tension-to-clear-extracellular-tumor-dna 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2699/trasplante-de-higado-de-donante-fallecido-y-supervivencia-postoperatoria-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2699/deceased-donor-liver-transplantation-and-postoperative-survival-in-patients-with-unresectable-colorectal-liver-metastases-a-retrospective-multicenter-study 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2698/los-carcinomas-colorectales-enteroblasticos-y-hepatoides-son-canceres-agresivos-con-un-inmunofenotipo-distintivo-mientras-que-el-carcinoma-de-celulas-claras-parece-representar-una-transformacion-de 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2698/enteroblastic-and-hepatoid-colorectal-carcinomas-are-aggressive-cancers-with-a-distinctive-immunophenotype-while-clear-cell-carcinoma-appears-to-represent-clear-cell-change-in-conventional-colorectal 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2692/variabilidad-genomica-de-la-linea-celular-hct116-identificada-mediante-secuenciacion-con-oxford-nanopore 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2692/genomic-variability-of-the-hct116-cell-line-identified-using-oxford-nanopore-sequencing 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2690/factores-pronosticos-y-predictivos-criticos-en-las-metastasis-hepaticas-del-cancer-colorrectal-un-analisis-exhaustivo-de-la-bibliografia-existente-y-perspectivas-de-futuro 2026-07-30 monthly 0.5 https://crcwarriors.org/articulo/2690/critical-prognostic-and-predictive-factors-in-colorectal-liver-metastasis-a-thorough-analysis-of-existing-literature-and-future-outlook 2026-07-30 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-07-23 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-07-21 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-07-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-07-28 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-07-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-07-01 monthly 0.4